Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CK Life Sciences International (Holdings), Inc. ( (HK:0775) ) just unveiled an announcement.
CK Life Sciences reported a loss of HK$126.6 million for 2024, primarily due to increased R&D investments and a decline in the fair value of its vineyard portfolio. The company is advancing its R&D efforts in non-opioid pain management solutions and therapeutic cancer vaccines, including a merger to form Dogwood Therapeutics for further development of Halneuron®. Additionally, CK Life Sciences is investing in liquid biopsy tests for early cancer detection, leveraging AI and cutting-edge technologies to enhance its cancer vaccine pipeline.
More about CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. is a company focused on research and development in the pharmaceuticals and diagnostics industry. It specializes in developing therapeutics for pain management and cancer, as well as innovative solutions for early cancer detection.
YTD Price Performance: 39.02%
Average Trading Volume: 3,889,201
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$5.29B
Learn more about 0775 stock on TipRanks’ Stock Analysis page.